Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine
ConclusionsThe results of this registry study suggest that in addition to the effect on the monthly number of migraine days documented in clinical trials, erenumab can significantly reduce the number of headache-related sick leave days and health care visits in employed patients with migraine managed in routine clinical practice.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | COVID-19 | Finland Health | Genetics | Headache | Health Management | Migraine | Neurology | Pandemics | Statistics | Study